Here are five things to know:
1. HBS and Quickset are highly injectable and resorbable calcium phosphate cements.
2. Both cements are commercialized in 23 countries.
3. Surgeons use radiographic guidance to perform a less invasive treatment for patients with bone marrow lesions using these cements.
4. The technology has three FDA 510(k) clearances and the new CE approvals strengthen the company’s market position.
5. GRAFTYS plans to set up a registry to demonstrate the efficacy of its products to treat post-traumatic bone marrow lesions.
More articles on orthopedic devices:
Medtronic on Dow Jones’ sustainability index: 5 key notes
Magec rod lines up with natural growth of children with scoliosis
Nextremity Solutions receives 7 patents
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
